Local Irritation of DA-125

DA-125의 국소자극성

  • 안병옥 (동아제약 주식회사 연구소) ;
  • 백남기 (동아제약 주식회사 연구소) ;
  • 이순복 (동아제약 주식회사 연구소) ;
  • 김원배 (동아제약 주식회사 연구소) ;
  • 양중익 (동아제약 주식회사 연구소) ;
  • 김부영 (국립보건안전연구원 특수독성과) ;
  • 김대병 (국립보건안전연구원 특수독성과) ;
  • 이종권 (국립보건안전연구원 특수독성과)
  • Published : 1993.04.01


DA-125, a new anthracycline derivative, shows significant anticancer activities. We conducted a study to examine the local irritating effect of DA-125 using mice and rabbits. In the skin test in mice, intradermal injection of 0.4 mg of DA-125, compared to a dosage of 0.2 mg of adriamycin, had weak irritating potentials to induce skin ulceration and erythematous induration. A dosage of 0.6 mg of DA-125 produced similar degree of lesions in perivascular irritation model to that of 0.2 mg of adriamycin, but the healing time was shorter in the case of mice treated with DA-125. In ocular irritation study in rabbit, the highest M.O.I.(mean ocular irritation index) of 0.5% DA-125 solution was 0.67, therefore DA-125 could be considered as a practically non-irritating anticancer agent. These results suggest that substitution of DA-125 for Adriamycin would reduces the possibility of outbreaks of local irritation and the severity of the lesions.